

INVESTOR FACT SHEET

3Q07

About AMO

Advanced Medical Optics, Inc. (AMO) [NYSE: EYE] is a global medical device leader focused on the discovery and delivery of innovative vision technologies that optimize the quality of life for people of all ages. We operate in large, established markets with favorable growth drivers.

A 2002 spin-off from Allergan, we have a 50-year heritage of innovation and sales in 60 countries. We operate manufacturing facilities on three continents and employ approximately 4,200 worldwide.

Key Market Facts

Fully diluted weighted average shares outstanding on 9/28/07: 60.2 million
Share price on 9/28/07: \$34.88
52-week range as of 9/28/07: \$30.59-40.25.
Market capitalization on 9/28/07: \$1.851 billion.

Recent Developments

AMO NASA LASIK Announcement (09/19/07)

Munnerlyn Edwin Land Medal (09/17/07)

AMO Introduces Three Refractive Technologies at ESCRS (09/10/07)

AMO Donates to UCI Eye Institute (08/27/07)

AMO Hires Derisio as VP of Regulatory – (08/27/07)

AMO Comments on BOL Letter (07/24/07)

Advanced Medical Optics Set to Re-Enter Multipurpose Solution Market in August (7/23/07)

AMO Announces FDA Approval of CustomVue Monovision (07/18/07)

Analysts:

Bear, Stearns & Co. – Rick Wise
BMO Capital Markets – Joanne Wuensch
Citigroup – Andrew Swanson
Cleveland Research – Steve Willoughby
Credit Suisse – Marc Goodman
FTN Midwest Research – Christopher Cooley
Jeffries & Co. – Peter Bye
Goldman Sachs & Co. – Lawrence Keusch
Lehman Brothers – Mathew Blackman
Morgan Stanley – Louise Chen
Piper Jaffray – Mark Mullikin
Wachovia Securities – Larry Biegelsen

Advanced Medical Optics, Inc. *Investment Highlights*

Global Vision Care Leader

Serving a full range of refractive vision care with superior, differentiated products delivered through an efficient global infrastructure

The Complete Refractive Solution

Uniquely positioned to capitalize on higher-growth, premium markets driven by demographics and technology

Commitment to Innovation


Building a pipeline of promising new technologies to stimulate growth across all businesses

Earnings Power & Financial Strength


Poised to deliver EPS growth and improving cash flow; healthy balance sheet provides financial flexibility

Global Revenue Mix – 3Q 2007

Total sales of \$273.2 million, up 5.6%



Sales Performance




This document contains forward-looking statements that are based on estimates, assumptions and projections. Important factors that could cause results to differ materially from those expected by management may be found in documents filed by the company with the Securities and Exchange Commission at "Investors" on www.amo-inc.com.

AMO
Vision. For life.

VISION CARE LIFE CYCLE

Virtually everyone requires some form of vision care during the course of their lifetime. AMO's fundamental strategy is to improve practitioner productivity and patient outcomes through a range of scientifically relevant products that span the vision care life cycle – from teens and young adults beginning contact lens wear, to baby boomers seeking refractive surgical options, to seniors requiring cataract surgery. Our goal is to compete aggressively where innovation can set us apart and give us a discernable market advantage.



AMO® Key Products

CATARACT / IMPLANT

WhiteStar Signature™ and Sovereign® phacoemulsification systems with WhiteStar® ICE™ technology used in cataract surgery

Healon® family of viscoelastic products used in ocular surgery

Sensar® monofocal IOL with patented OptiEdge™ design with uninterrupted 360-degree barrier protection

Tecnis® monofocal IOL with modified prolate design for reduced spherical aberrations and improved functional vision

Tecnis® Multifocal IOL with a diffractive pattern on one side and modified prolate surface on the other to provide near, intermediate and distance vision

Verisyse® phakic IOL for correction of myopia

ReZoom® multifocal refractive IOL for cataract patients

Unfolder® series of IOL insertion systems used in cataract and refractive surgery

Baerveldt® glaucoma implant

LASER VISION CORRECTION

CustomVue® wavefront-guided custom LASIK treatment that customizes a procedure based on the specific refractive error of each patient

WaveScan® diagnostic system that captures comprehensive fingerprint of a patient's eye

STAR S4 IR® excimer laser vision correction system

Iris Registration fully-automated method of aligning and registering wavefront correction for CustomVue® treatments

IntraLase® FS Laser system for the creation of precise corneal flaps as the first step in LASIK surgery

EYE CARE

COMPLETE® multipurpose solution for contact lens cleaning and comfort

blink Contacts™ and COMPLETE® Blink-N-Clean® lubricating eye drops for contact lens wearers

Oxysept®1 Step, Consept®1 Step and Ultracare® hydrogen peroxide systems for soft contact lens cleaning and disinfection

Cataract Surgery is performed to restore clear vision when the eye's natural lens becomes hard and opaque. Using phacoemulsification, a surgeon inserts a hollow ultrasound needle through a small incision in the cornea to soften and break up the lens into fragments, which are aspirated from the capsular bag. A flexible, folded IOL is inserted through the incision into the lens capsule. During the procedure, viscoelastic is injected into the eye to protect ocular surfaces and provide the surgeon room to operate.

Refractive Surgery is performed to address abnormal eye conditions whereby an image does not focus properly on the retina. The predominant procedure is LASIK, in which a microkeratome device or femtosecond laser creates a corneal flap and an excimer laser reshapes the cornea. IOLs are also being used increasingly to address refractive disorders. They include traditional IOLs, where the natural lens is removed, and phakic IOLs, where the natural lens remains in place.

Eye Care Products are used to clean, disinfect and lubricate contact lenses and make them safe, effective and comfortable. One-bottle, multipurpose solutions are the predominant lens care regimen. Rewetting drops provide contact lens wearers added comfort and relief from dryness.

Investor Relations Contact:

Sheree Aronson
CVP, Corp. Communications,
Investor Relations and Market
Research
(714) 247-8290 or
sheree.aronson@amo-inc.com